A shortage of large, sterile plastic bags used to grow vaccine cells has hobbled Novavax's work to scale up its COVID-19 shot production.
CEO Stan Erck told the Observer that the shortage of the 2,000-liter bags is a threat to the global supply of vaccines.
In late March, a European Union official told Reuters that Novavax had delayed signing a contract to supply COVID-19 vaccines to the EU because it was struggling to secure some raw materials.
Nessun commento:
Posta un commento